Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845

BACKGROUND: In study TMC647055HPC2001, a 3-direct-acting-antiviral (DAA) regimen combining NS3/4A protease inhibitor simeprevir (SMV), non-nucleoside NS5B inhibitor TMC647055/ritonavir (RTV) and NS5A inhibitor JNJ-56914845 resulted in high sustained virologic response 12 weeks after actual end of tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Vijgen, Leen, Thys, Kim, Vandebosch, An, Van Remoortere, Pieter, Verloes, René, De Meyer, Sandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452362/
https://www.ncbi.nlm.nih.gov/pubmed/28569206
http://dx.doi.org/10.1186/s12985-017-0760-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452362/
https://www.ncbi.nlm.nih.gov/pubmed/28569206
http://dx.doi.org/10.1186/s12985-017-0760-2

Ejemplares similares